- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Fuji lands CR deal with Premier group
Fuji lands CR deal with Premier groupFuji Medical Systems USA has agreed to a limited-time offer to sell its CR readers at special pricing to members of the Premier group purchasing organization. The agreement could bring more than $25 million
Fuji lands CR deal with Premier group
Fuji Medical Systems USA has agreed to a limited-time offer to sell its CR readers at special pricing to members of the Premier group purchasing organization. The agreement could bring more than $25 million in sales to the Stamford, CT-based vendor. Premier's members have until May 1 to take advantage of the deal, which covers Fuji's AC-3, FCR-5000, FCR-9000, and FCR-9501 CR systems.
While digital detectors have drawn attention in the radiology community, there is clearly a strong demand for CR. In fact, Fuji believes prospective purchasers are increasingly looking to use CR in diverse types of applications, said Clay Larsen, managing director at Fuji.
"Until now, CR has been looked at primarily as a great solution for ICU/CCU, and the ER department," Larsen said. "Now the adoption rate is heating up to place the systems in total departmental solutions, trying to get the entire radiographic case load into a digital format. The adoption rate is getting a broader footprint into institutions."
- Search again
- Homepage
New Study Assesses Long-Term Outcomes of PSMA PET Use in PCa Recurrence Cases
October 24th 2024For patients with biochemical recurrence of prostate cancer, PSMA PET imaging may facilitate a 12.8 percent lower incidence of prostate cancer mortality in contrast to the combination of CT and bone scan, according to long-term outcome estimates from a new decision-analytic modeling study.
Can Diffusion MRI Predict Patient Response to Neoadjuvant Chemotherapy for Breast Cancer?
October 23rd 2024A model emphasizing time-dependent diffusion MRI was 15 percent more effective than apparent diffusion coefficient (ADC) measurements at predicting pathologic complete response to neoadjuvant chemotherapy for women with breast cancer, according to new research.
